glp-1 egfr cut off Updated evidence on cardiovascular and renal effects of receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives | Cardiovascular Diabetology Chronic Kidney Disease | Ozempic®

These findings represent substantial improvements over traditional anti-obesity medications and approach the efficacy levels historically associated with bariatric surgery

Over the past few decades several hormones from various body systems involved in food intake have been targeted as potential treatments for obesity and diabetes, but GLP-1 seems to be the one thats risen to the top, at least for pharmacotherapy, says Scott Kanoski, a behavioral neuroscientist and professor at the University of Southern California

This is significant where Medicaid enrollment is substantial

GLP-1s reduce overall body fat, but do not sculpt or contour specific areas